Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US.
It is a $48.1B healthcare company. Revenue grew 4.1% over the last year, it keeps 4¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 63.2× earnings — near the highest of its own history.
- Website
- tevapharm.com
- Location
- Tel Aviv
- Employees
- 32 842
- Sector
- Healthcare
- Founded
- 1901
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Valuation and Health lag behind.
Valuation37
- P/E vs own history100th pct · 0/25
- FCF yield2.8% · 5/25
- P/S2.6x · 20/25
- EV/EBITDA24.5x · 12/25
Growth56
- Revenue CAGR2.1% · 6/25
- Net income CAGR35.6% · 25/25
- EPS CAGR ~5Yn/a · 0/25
- Fwd implied growth341.6% · 25/25
Profitability50
- ROIC22.8% · 20/25
- ROE9.1% · 12/25
- Net margin4.1% · 6/25
- Operating margin9.3% · 12/25
Health44
- Altman Z0.63 · 3/25
- Current ratio0.88 · 6/25
- Interest coverage2.4x · 10/25
- Net cash / debtNet cash · 25/25
Quality53
- Piotroski F7/9 · 22/25
- Beneish M-2.51 · 25/25
- FCF conversionn/a · 0/25
- Margin stabilityσ 19.0% · 6/25
Moat58
- ROIC >12% years5/9 yrs · 13/25
- Median gross margin47.8% · 20/25
- FCF-positive years9/9 yrs · 25/25
- Worst-year net marginworst -72.7% · 0/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- FY2025FinancialBest year on record$1.41B net income
- FY2021FinancialTurned profitable$417M net income after a loss year
- FY2021FinancialBecame debt-freecash now exceeds total debt
- FY2017FinancialRevenue already above $10B$22.4B in first reported year
- FY2017FinancialPositive free cash flow every year since9-year streak
- 2015AcquisitionTeva acquired Auspex Pharmaceuticals for $3.5 billion growing its CNS portfolio
- 2011AcquisitionTeva bought Cephalon for US$6.8 billion
- Dec 23, 2008AcquisitionTeva acquired Barr Pharmaceuticals for $7.5 billion, making Barr and Pliva (which Barr bought…
- 2006AcquisitionTeva acquired its U.S. rival Ivax Corporation for $7.4 billion
- 2003AcquisitionTeva announced its intentions to acquire Sicor Inc. for $3.4 billion
- 1995AcquisitionTeva acquired Biogal Gyógyszergyár Rt. (Debrecen, Hungary) and acquired ICI (Italy)
- 1980AcquisitionTeva acquired Ikapharm, then Israel's second largest drug manufacturer
- 1964AcquisitionAssia and Zori merged and in 1968 acquired a controlling stake in Teva
- 1951IPOFeuchtwanger initiated an initial public offering to raise capital through the newly founded Tel-Aviv Stock…
- 1901FoundedTeva's earliest predecessor was SLE, Ltd., a wholesale drug business founded in 1901 in Ottoman Empire's…
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (52.9%)
- Net cash position after subtracting debt from cash
- High returns on invested capital (ROIC 22.8%)
- Piotroski F-Score 7/9 — fundamentally strong checklist
Watch-outs
- Altman Z-Score 0.63 — elevated financial-distress risk
- Net debt would take ~9.8 years of free cash flow to repay
- Loss-making in 7 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+4.1% YoY
- Profitable — makes more than it spends$706M TTM
- Profit growing — earnings are higher than last year+186.0% YoY
- Generates cash — cash left after running and investing$1.35B TTM
- Debt under control — could handle its obligationsmore cash than debt
- Established company — not a micro-cap — lower blow-up risk$48.1B market cap
- Not printing shares — share count not ballooning — you keep your slice+6.2% shares over ~5y
- Proven track record — years of profitability behind it2/9 profitable years
- Financially stable — balance sheet not near distressAltman Z 0.6 — distress
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsP/E 63.2
Peer comparisonTeva Pharmaceutical Industries Limited vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| TEVA this company | $48.1B | 63.2 | +4.1% | 4.1% | Strained |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: TEVA vs LLY · TEVA vs JNJ · TEVA vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2017–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/TEVA
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of TEVA on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $41.21 · market cap $48.1B.